Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase III study assessing LentiGlobin for sickle cell disease (SCD)

Next Previous
Trial Profile

A second phase III study assessing LentiGlobin for sickle cell disease (SCD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 11 May 2020 According to a Bluebird media release, the company has prioritized investment in R&D expenses, including an indefinite pause of the HGB-211 clinical study in SCD patients at high risk of stroke, adjustment to the timing of investment in ongoing clinical studies to reflect COVID-19 related delays in enrollment, reduction or elimination of investment in certain preclinical programs, and other cost-reduction measures.
  • 20 Feb 2020 New trial record
  • 18 Feb 2020 According to a Bluebird media release, this trial along with HGB-210 is intended to support potential approval of LentiGlobin for Sickle-cell-anaemia in pediatric patients at elevated stroke risk.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top